Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China
The leading principal investigators (leading PIs) of the phase I clinical trial are Professor Zhang Jing and AssociateProfessor Wu Xiaojie from Huashan Hospital affiliated to Fudan University.
- The leading principal investigators (leading PIs) of the phase I clinical trial are Professor Zhang Jing and AssociateProfessor Wu Xiaojie from Huashan Hospital affiliated to Fudan University.
- Dr. Youzhi Tong, founder, Chairman, and CEO of Kintor Pharma, commented, "Both indications of AGA and acne have great unmet clinical needs.
- As the world's first company to develop a topical AR-PROTAC compound, Kintor is currently conducting phase I clinical trials of GT20029 in China and the United States.
- In July 2021, Kintor announced the dosing of first batch of subjects in its China phase I clinical trial of GT20029.In February 2022,Kintor announced the dosing of first subjectin its USphase I clinical trial of GT20029.